New turmoil inside the FDA as Tracy Beth Høeg takes over a key drug watchdog office

The sudden rise of Dr. Tracy Beth Høeg to one of the Food and Drug Administration’s most powerful posts has stunned many inside the agency. Overnight, a physician best known for questioning parts of the U.S. vaccine program has been placed in charge of the FDA office that oversees the safety and approval of most prescription and over-the-counter drugs in America.

Her promotion, made after the abrupt departure of longtime cancer drug expert Dr. Richard Pazdur, has been greeted with deep unease by multiple senior FDA scientists. They fear the move could politicize a traditionally science-driven office and unsettle drug makers that rely on the FDA as a predictable regulator.

A shock promotion in a high-stakes job

Høeg was tapped as acting director of the FDA’s Center for Drug Evaluation and Research (CDER), the division responsible for reviewing new drug applications, monitoring the safety of medicines already on the market, and setting standards used by doctors and patients across the country. It is one of the most influential regulatory jobs in global pharmaceuticals.

What has rattled insiders is not only the speed of the appointment, but also Høeg’s background. She is a sports medicine physician and epidemiologist with a track record of public commentary on vaccines, but critics say she has limited direct experience running large regulatory programs, overseeing drug reviews, or conducting clinical trials. Several current officials told reporters the choice could trigger resignations among career staff who worry that the decision reflects political priorities more than scientific credentials.

Vaccine skepticism and a controversial COVID memo

Høeg has been a polarizing figure in vaccine debates. Before joining the FDA, she gained attention for raising alarms about myocarditis, a rare form of heart inflammation that can occur after COVID vaccination, particularly in younger males. While many scientists agree myocarditis is a real risk that must be monitored, Høeg’s critics say she has consistently emphasized potential harms more than the well-documented benefits of the shots.

Those tensions intensified after she joined the FDA as a senior adviser on vaccine policy. According to documents obtained by journalists, Høeg helped write an internal memo asserting that at least 10 children had died after – and specifically because of – COVID vaccination. The document reportedly offered no supporting data, and outside experts quickly questioned the claim. Federal health officials later said they would release more information, but the episode heightened fears that vaccine safety was being reframed through a political lens rather than a purely scientific one.

Questions about vaccine schedules at a pivotal CDC meeting

Høeg’s views also took center stage at a recent meeting of the Centers for Disease Control and Prevention’s vaccine advisory committee, where she served as the FDA’s representative. The panel was reviewing long-standing guidance on the timing of the hepatitis B vaccine, which for decades has included a dose at birth for all infants.

During the public session, Høeg questioned why the United States recommends more vaccines, and at earlier ages, than some other high-income countries. She asked whether the broader U.S. schedule is truly justified for children in lower-risk groups and suggested that the nation may be an “outlier” in its approach. Pediatric leaders later pushed back, pointing to a large body of research showing that the American schedule is broadly in line with other developed nations when differences in disease patterns and health systems are considered.

Fears of politicization and a shaken drug pipeline

Inside the FDA, the central worry is not just Høeg’s skepticism on vaccines, but what her leadership might signal for the entire drug center. CDER is the gatekeeper for everything from cancer therapies and heart medications to over-the-counter pain relievers. Drug companies invest billions of dollars and years of research into winning the office’s approval.

Some senior officials warn that if CDER is perceived as driven by ideology rather than data, companies could hesitate to bring their most innovative products to the U.S. market first. They fear sponsors may increasingly look to Europe or other regions as the primary venue for critical approvals, seeing those regulators as more stable and less vulnerable to political swings. That, in turn, could slow American patients’ access to cutting-edge treatments and diminish the FDA’s global standing.

Leadership churn adds to instability

Høeg is the latest in a rapid succession of leaders at the drug center. This year alone, the office has cycled through multiple directors, including Pazdur, a veteran cancer specialist who agreed to take the job on the condition that the FDA commissioner would not interfere in his work. According to people familiar with the situation, that arrangement quickly broke down, and Pazdur resigned after clashing with the agency’s top political appointees.

The turnover has left staff on edge. Many worry that frequent leadership changes, combined with the elevation of a controversial figure, could erode morale and drive experienced scientists out of the agency. Some have described the atmosphere as one of shock and uncertainty, with long-time employees unsure how much latitude they will have to challenge decisions they see as undermining established regulatory standards.

A commissioner’s vote of confidence — and a test of trust

Publicly, FDA Commissioner Marty Makary has offered a strong endorsement of Høeg, praising her as the right person to modernize the drug office and touting her commitment to transparency and “rigorous science.” In her own statement, Høeg pledged to base decisions on evidence and to implement important changes efficiently.

Her supporters argue that skeptics are overreacting and that someone willing to question assumptions about vaccines and other products could strengthen rather than weaken the agency’s scientific process. They say rigorous debate, including about potential side effects and risk-benefit tradeoffs, is exactly what a science-based regulator should encourage.

What’s next for patients, providers and the FDA

For patients and health care professionals, the immediate impact of Høeg’s appointment may be hard to see. Most drugs already on the market will remain available, and existing safety systems will continue to operate. But over time, shifts in how the FDA weighs evidence, communicates risks, and confronts political pressure could shape what medications get approved — and how quickly.

The larger question is whether the agency can maintain public trust in an era when vaccines and drug approvals are increasingly dragged into partisan fights. Høeg’s tenure at the head of CDER will be closely watched as an early test of that balance: can a regulator led by a figure deeply skeptical of parts of the vaccine program still convince Americans that its decisions are guided by data, not politics?